Navigation Links
Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
Date:6/10/2008

PARIS, France - 11 June 2008 Findings from two new Phase 3 studies showed that patients receiving every four-week subcutaneous injections of golimumab (CNTO 148) 50 mg and 100 mg and weekly methotrexate (MTX) experienced significant improvements in the signs and symptoms of rheumatoid arthritis (RA) as well as in physical function and disease activity, with some patients achieving remission as measured by Disease Activity Score (DAS28). Findings from two multicenter, randomized, double-blind, placebo-controlled Phase 3 studies showed the efficacy of golimumab in two important populations MTX-naive patients and patients with active RA despite ongoing treatment with MTX. These data were presented at the European League Against Rheumatism (EULAR) Annual Congress of Rheumatology. Golimumab is currently in the most comprehensive initial Phase 3 development program to date for an anti-tumor necrosis factor (TNF)-alpha biologic therapy with ongoing studies for the treatment of RA, psoriatic arthritis and ankylosing spondylitis.

In the study, GOlimumab FOR subjects With Active RA Despite MTX (GO-FORWARD), both the 50 mg and 100 mg doses of golimumab were studied in patients whose disease was active despite ongoing treatment with MTX. At week 14, 55 percent of patients receiving golimumab 50 mg plus MTX and 56 percent receiving golimumab 100 mg plus MTX achieved at least 20 percent improvement in signs and symptoms of RA (ACR 20), compared to 33 percent of patients receiving placebo and MTX (p<0.01 and p<0.001, respectively). Improvements were seen as early as first clinical assessment, which was four weeks after the first golimumab injection, and generally continued to improve over time.

"The data in this study demonstrate that golimumab is beneficial in improving numerous disease parameters, including inducing remission, in patients whose disease was active despite ongoing treatment with methotrexate," said Edward Keystone, M.D., FRCPC, dir
'/>"/>

Contact: Brian Kenney
bkenney1@cntus.jnj.com
215-620-0111
Centocor, Inc.
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
6. Phase III Trial Finds Pharmaxis Bronchitol Effective
7. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
8. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
9. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
10. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
11. Stimuvax(R) Phase II data highlight three-year survival results for patients with non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... NEW YORK , July 29, 2015 /PRNewswire/ ... neuropathology testing, announces increased partnerships with VA and ... offers Epidermal Nerve Fiber Density (ENFD) and Sweat ... of small fiber neuropathy ( https://therapath.com/skin ). ... Epidermal Nerve Fiber Density (ENFD) on punch skin ...
(Date:7/29/2015)... ... , ... The third Medical Innovation Impact Index (MI3) Alert considers FDA processes ... The current system received a score of 0 (range -10 to +10) for its ... of Fairleigh Dickinson University’s ( FDU ) Rothman Institute of Innovation and Entrepreneurship. Several ...
(Date:7/29/2015)... ... July 29, 2015 , ... Finding gooey or crusty material in the ... there are a considerable number of terms in popular use to describe it, ophthalmologists ... a mixture of mucus, blood cells, skin cells and dust, but until now there ...
(Date:7/29/2015)... ... ... Costello served as Lead Levee Design Engineering Manager for a feasibility study of ... future storm surge flooding, such as occurred in Hurricane Ike in 2008. , ... protection, Costello also balanced socio-economic and environmental needs and concerns. The team ...
Breaking Biology Technology:Neuropathology services for VA and Military health systems 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 2Third Medical Innovation Impact Index Issued by Fairleigh Dickinson University’s Initiative for Patient-Centered Innovation (iPCI) 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4Preventing Storm Surge Flooding in Houston 2
... officials announced today a five-year agreement with K.S.R. Educational ... training in nanomedicine and nanotechnology. "We are very ... 16 institutions of higher education in Tamil Nadu, India," ... has the same commitment to deliver quality education to ...
... Corp. (NASDAQ: KOOL ), a leading supplier ... adult stem cells, said today that its submission for ... to concentrate stem cells from cord blood, has been ... in China. This represents the successful completion of product ...
... Corporation (NASDAQ: UTHR ) (the "Company") today announced ... conditions, $210 million aggregate principal amount of convertible senior notes ... 144A under the Securities Act of 1933, as amended (the ... initial purchaser of the notes an option to purchase up ...
Cached Biology Technology:MU signs academic agreement with K.S.R. Educational Institutions of India 2ThermoGenesis Announces Acceptance of AXP® Submission by Regulatory Body in China 2ThermoGenesis Announces Acceptance of AXP® Submission by Regulatory Body in China 3United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program 2United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program 3United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program 4
(Date:6/24/2015)... 2015 The biologics safety testing market is ... the market include growth of the pharmaceutical and biological ... Over the years, the number of drug approvals in ... the FDA approved 225 drug applications and Health Canada ... Europe accounted for 3,822 of the pharmaceutical ...
(Date:6/24/2015)... SAN JOSE, Calif. , June 24, 2015 ... leading developer of human interface solutions, today announced ... fingerprint sensor to provide secure authentication for its ... Having recently reached more than 200 million shipments ... shipment with Sharp reinforces Synaptics, strength, scalability and ...
(Date:6/24/2015)... 2015 Biometry authentication provider KeyLemon today ... solution one face in. Logo ... face in, entering the expanding biometric authentication market ... biometric answer to the password problem. With advanced ... with KeyLemon, one face in allows users to ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
... pathogens deploy effector proteins as part of their ,molecular ... New research has revealed the structure of a bacterial ... host. , Gram-negative bacterial pathogens can deliver effector proteins ... to manipulate host cell processes for the benefit of ...
... - Scientists at the U.S. Department of Energy,s Brookhaven ... mechanism plants use to limit the production of fatty ... biochemical pathways to increase the production of plant oils ... "Now that we understand how this system operates ...
... diversity is increasingly threatening Mother Nature,s ability to provide humans ... and protection from pests and disease, according to a sweeping ... of ecologists, including biologists from the University of British Columbia ... the June 7 edition of the journal Nature ...
Cached Biology News:The activity of a bacterial effector protein seen in molecular detail 2Scientists identify mechanism for regulating plant oil production 2Scientists identify mechanism for regulating plant oil production 3Loss of biodiversity increasingly threatens human well-being: UBC, University of Michigan research 2
...
... Human CD66 acd Recognizes human ... neutrophils and cells in some cases ... with transfectants containing BGPa, NCA and ... Immunogen: Human ...
Request Info...
... GOAT ANTI-MOUSE IgG+IgA+IgM (H+L) ... with highly purified horseradish ... antibody has been absorbed ... fetal bovine, horse, goat, ...
Biology Products: